Cost-Effectiveness Study of Difamilast 1% for the Treatment of Atopic Dermatitis in Adult Japanese Patients
Abstract Introduction Difamilast has proven to be an effective treatment for the treatment of atopic dermatitis (AD) in Japan, but its cost-effectiveness remains unknown. Therefore, the objective of the current study was to determine the cost-effectiveness of difamilast 1% compared with delgocitinib...
Saved in:
Main Authors: | Takeshi Nakahara (Author), Shinichi Noto (Author), Miyuki Matsukawa (Author), Hiroe Takeda (Author), Yilong Zhang (Author), Tomohiro Kondo (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis
by: Takeshi Nakahara, et al.
Published: (2024) -
An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis
by: Hidehisa Saeki, et al.
Published: (2024) -
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2022) -
Current status of the satisfaction levels of adult patients receiving drugs for atopic dermatitis and chronic urticaria
by: Sakae Kaneko, et al.
Published: (2022) -
Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting
by: Ken Igawa, et al.
Published: (2023)